DiaGenic signs agreement with Ferrer inCode

DiaGenic signs agreement with Ferrer inCode for distribution of ADtect® in Spain, Germany, Belgium, the Netherlands, Luxemburg, France, Italy, and Portugal.

DiaGenic announces that it has signed an agreement for exclusive distribution of ADtect® in major European countries with Ferrer inCode, a biotech subsidiary of Grupo Ferrer Internacional. ADtect® uniquely uses peripheral blood as the sample material to provide early non-invasive diagnosis of Alzheimer’s disease. “Early detection enables subsequent early initiation of active management strategies which may preserve the patients’ level of function for longer and increases the chances of delaying the progression of the disease”, said DiaGenic CEO Erik Christensen, M.D., Ph.D. “Current evidence suggests that pharmacological treatments and caregiver interventions can delay entry into nursing homes, thus reducing healthcare costs. However, these cost savings are not being realized because many patients with Alzheimer’s disease are either not diagnosed or diagnosed at a late stage of the disease. We envisage ADtect® with its rapid and convenient sample collection playing a front line role.” “As front runners in the field of personalized medicine, we are delighted to offer ADtect® to professionals and patients in our core markets. The field of CNS is fast moving and we will continue to see important developments within treatment and medical care of Alzheimer patients. Therefore we strongly believe in an easy to use and non-invasive test such as ADtect® which can provide early detection of Alzheimer’s disease and thereby improve quality of life”, said Alfredo Gracia M.D., Ph.D, Ferrer inCode’s Chief Scientific Officer. Following this latest distribution agreement, for the period from year 2010 up to and including year 2013 cumulative minimum volumes ADtect® in 17 European countries total approximately 85,000 tests. Please find joint press release attached. Contact person: Erik Christensen, CEO Telephone: + 47 95939918 E-mail: erik.christensen@diagenic.com About DiaGenic ASA DiaGenic is an innovative Norwegian biotechnology company that seeks to create value for patients, partners, and investors by developing new and more patient friendly methods for early detection of diseases. DiaGenic is currently a world leader in analyzing gene expression signatures related to disease in easily available clinical samples such as peripheral blood. This unique method is based on the principle that even when a disease is localized at a specific part of the body, secondary responses, which are also characteristic of the disease, can be measured in other parts. Significant potential in numerous diseases such as breast cancer and Alzheimer's disease has been identified. The company has been granted patents in the U.S. and Europe. DiaGenic is listed on the Oslo Stock Exchange. For more information visit www.diagenic.com About Ferrer inCode and Grupo Ferrer Internacional Ferrer inCode is the biotech subsidiary of Grupo Ferrer Internacional, working specifically in the field of personalized medicine as a provider of diagnostic orientation, prognosis and prediction services based chiefly on genomics, proteomics, metabolomics and bioinformatics. The vision of Ferrer inCode is to help doctors make the most accurate clinical decisions for every patient through advanced biotechnological services. Grupo Ferrer Internacional is a privately held European R&D-based pharmaco-chemical and medical device company headquartered in Barcelona, Spain. Ferrer operates today in over 60 countries with the overall aim of improving people’s health and quality of life. Based on its policy of continuous expansion throughout the world, Ferrer has established strong industrial and commercial operations in Europe and has extensive commercial experience in Latin America, Africa, the Middle East and Far East. For more information on Ferrer,visit www.ferrergrupo.com or www.ferrerincode.com.